The Zhitong Finance App learned that on Thursday, LLY.US (LLY.US) went high. As of press release, it had an increase of nearly 9%, with a market capitalization of 1.32 trillion US dollars, and a cumulative increase of more than 20% since October. According to the news, Lilly announced pre-market results for the third quarter of 2026: revenue of US$24.397 billion, a year-on-year increase of 39%, higher than LSEG's estimate of about US$22.6 billion, with sales increasing by 53% and actual prices falling by 15%. Reported net profit of US$6.451 billion and earnings per share of US$7.22, up 16% year over year; non-GAAP earnings per share were US$7.48, up 7% year over year, higher than the LSEG/IBES forecast of US$6.49.
Two core products continued to grow: Mounjaro's global revenue was US$10.723 billion, up 65% year on year, Zepbound US$5.352 billion, up 49%, KeyProducts totaled US$17.1 billion, and revenue in the fields of immunology, oncology, and neuroscience doubled year over year. US revenue increased 34% to US$15.1 billion; revenue from outside the US increased 47% to US$9.3 billion, and sales increased 76%, but prices fell 29% due to Mounjaro's inclusion in China's national health insurance catalogue.
In terms of guidance, the full-year revenue guidance was raised from US$85 billion to US$87 billion to US$91 billion to US$92 billion, the profit margin on performance was raised from 49.0% — 50.5% to 52.0% — 52.5%, and the tax rate increased from 18% to 19% — 20%; however, the bottom line profit improvement was offset by the above acquisition R&D expenses, and the adjusted earnings per share guide for the whole year was lowered from US$35.50-36.50 to US$35.00-36.00.